Variant position: 36 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 80 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human CFLTGVFSQGGQ-------------------------VDCGEFQD PKVYCTRESNPHCGSDGQTYG
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
24 – 80 Serine protease inhibitor Kazal-type 6
24 – 80 Kazal-like
24 – 24 Pyrrolidone carboxylic acid
30 – 62
34 – 37
Isolation of SPINK6 in human skin: selective inhibitor of kallikrein-related peptidases.
Meyer-Hoffert U.; Wu Z.; Kantyka T.; Fischer J.; Latendorf T.; Hansmann B.; Bartels J.; He Y.; Glaser R.; Schroder J.M.;
J. Biol. Chem. 285:32174-32181(2010)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; FUNCTION; VARIANT THR-36;
The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]; VARIANT THR-36;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.